Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States-Reference-Cited by-同舟云学术

Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States

Published:2015-10-11 Issue:5 Volume:173 Page:1183-1190
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Kimball A.B.¹,Schenfeld J.²,Accortt N.A.³,Anthony M.S.³,Rothman K.J.⁴,Pariser D.⁵

Affiliation:

1. Department of Dermatology Massachusetts General Hospital 50 Staniford Street #240 Boston MA 02114 U.S.A.

2. DOCS Global, Inc. North Wales PA U.S.A.

3. Amgen Inc. Thousand Oaks CA U.S.A.

4. RTI International Research Triangle Park NC U.S.A.

5. Eastern Virginia Medical School and Virginia Clinical Research, Inc. Norfolk VA U.S.A.

Funder

Abbott Laboratories

Amgen

Merck

Pfizer

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.14068

Reference29 articles.

1. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

2. Epidemiology of comorbidities in psoriasis

3. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies

4. On the missing link between inflammation and cancer;Alexandrescu DT;Dermatol Online J,2011

5. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials;Dermatology and Therapy;2024-08-17

2. Serious adverse events associated with systemic treatments for psoriasis: a network meta-analysis of observational studies and randomized controlled trials;Cochrane Database of Systematic Reviews;2024-04-18

3. Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials;British Journal of Dermatology;2024-01-16

4. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up;Journal of the American Academy of Dermatology;2023-12

5. The Effects of Biologics on Hematologic Malignancy Development in Patients with Ankylosing Spondylitis, Psoriasis, or Psoriatic Arthritis: A National Cohort Study;Biomedicines;2023-09-11